多期相68Ga-PSMA PET/CT在PSA低于1 ng/mL的前列腺癌患者早期复发检测中的应用:一项纳入135例患者的前瞻性研究
这项前瞻性单中心研究纳入135例根治性前列腺切除术后生化复发且PSA低于1 ng/mL的前列腺癌患者,行动态、全身标准及延迟多期相68Ga-PSMA PET/CT。多期相信息使49.6%患者检出病灶,PSA 0.5-1.0 ng/mL组检出率71.4%;PSA低于0.5 ng/mL组检出率有限。多期相采集有助于判定可疑病灶。
要点
- 多期相采集在49.6%的患者中检出116个病灶,包括22个局部复发、63个淋巴结和31个远处转移。
- PSA低于0.2、0.2-0.5、0.5-1.0 ng/mL组的检出率分别为31.8%、44.9%、71.4%。
- 动态或延迟期相使25.9%患者的可疑病灶判定更明确、诊断性能提高。
核心结论
- 68Ga-PSMA PET/CT对PSA 0.5-1.0 ng/mL患者的早期复发检测显示出应用前景,但在PSA低于0.5 ng/mL患者中价值有限。
- 多期相68Ga-PSMA PET/CT有助于更明确地判定可疑病灶。
- 动态图像可能为前列腺床评估提供有用信息,而延迟采集似乎对澄清可疑病灶影响更大。
研究设计与样本
- 前瞻性单中心研究,纳入135例生化复发且PSA低于1 ng/mL的前列腺癌患者。
- 所有患者均接受初始前列腺切除术,其中19.3%接受额外放疗,7.4%接受雄激素剥夺治疗。
- 患者接受前列腺床动态采集(注射后1-8分钟)、全身标准采集(注射后60分钟)及有限床位延迟采集(注射后120-150分钟)。
- 图像由2名委员会认证的核医学专家独立阅片,结合视觉与半定量分析及形态学(如MRI)或临床随访结果判定病灶良恶性。
主要发现
- 综合所有期相信息,在49.6%的患者中检出116个病灶(22个局部复发、63个淋巴结、31个远处转移)。
- PSA低于0.2 ng/mL、0.2≤PSA<0.5、0.5≤PSA<1组的检出率分别为31.8%、44.9%、71.4%。
- 额外动态或延迟期相使25.9%患者的可疑病灶判定更明确、诊断性能更高。
- 单独动态图像和单独延迟图像分别使前列腺床(31.4%)和其他病灶(淋巴结或骨)(20%)的可疑表现得到更好判读。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The main objective of this prospective study was to determine the impact of multiphasic acquisition of 68Ga-PSMA PET/CT in the detection of recurrent prostate cancer in the early stage of biochemical recurrence with a prostate-specific antigen (PSA) level of less than 1 ng/mL. Also, 68Ga-PSMA PET/CT positivity was correlated with clinical parameters for the assessment of predictive markers. Methods: A prospective monocentric study was conducted on 135 prostate cancer patients with biochemical recurrence and a PSA level of less than 1 ng/mL. All patients had undergone initial prostatectomy, with additional radiation therapy in 19.3% of patients and androgen-deprivation therapy in 7.4%. The patients underwent dynamic acquisitions from the prostate bed (1-8 min after injection), standard whole-body acquisitions (60 min after injection), and limited-bed-position delayed acquisitions (120-150 min after injection). The studies were reviewed by 2 board-certified nuclear medicine specialists, independently. A combination of visual and semiquantitative analyses and correlation with morphologic (e.g., MRI) or clinical follow-up findings was used for the final interpretation of lesions as benign or malignant. 68Ga-prostate-specific membrane antigen (PSMA) PET/CT positivity was also correlated with primary clinical findings. Results: Incorporating the information from all phases, we were able to detect 116 lesions in 49.6% of patients (22 local recurrences, 63 lymph nodes, and 31 distant metastases). The detection rates were 31.8%, 44.9%, and 71.4% for PSA < 0.2 ng/mL, 0.2 ≤ PSA < 0.5, and 0.5 ≤ PSA < 1, respectively. Additional dynamic or delayed phases resulted in better determination of equivocal lesions and a higher diagnostic performance in 25.9% of patients. Stand-alone dynamic and delayed images led to better interpretation of equivocal findings in the prostate bed (31.4%) and in other lesions (lymph node or bone) (20%), respectively. Conclusion:68Ga-PSMA PET/CT showed promise for early detection of recurrent disease in patients with a PSA level of 0.5-1.0 ng/mL. However, it showed limited value in patients with a PSA level of less than 0.5 ng/mL. Multiphasic 68Ga-PSMA PET/CT led to a better determination of equivocal findings. Although dynamic images may provide helpful information for assessment of the prostate bed, delayed acquisitions seem to have a greater impact in clarifying equivocal findings.
引用
- Beheshti M, Manafi-Farid R, Geinitz H, et al. Multiphasic 68Ga-PSMA PET/CT in the Detection of Early Recurrence in Prostate Cancer Patients with a PSA Level of Less Than 1 ng/mL: A Prospective Study of 135 Patients. J Nucl Med. 2020. PMID: 32060214. doi:10.2967/jnumed.119.238071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。